Some people carry APOE ε4, one of the strongest common genetic risk factors for Alzheimer's disease, yet never develop it, staying mentally sharp well into their 80s. Researchers at Columbia University say they have finally worked out why, in a study that identifies the biological mechanism behind a rare genetic defense.
The new findings, published in the journal Nature Aging, build on a discovery the same team made two years ago: some people who carry APOE ε4 also carry a rare, separate mutation in the gene that makes fibronectin, a protein found in the blood-brain barrier, the tightly sealed lining around the brain's blood vessels that controls what can pass into brain tissue. That earlier work showed the mutation seemed to protect against Alzheimer's. The new study explains how.
A Barrier Clogged From Within
Using human brain tissue and cerebrospinal fluid, single-cell sequencing, spatial imaging, stem-cell models, lab-grown blood vessels, and studies in zebrafish and mice, the researchers traced a consistent chain of events: APOE ε4 drives the brain's blood vessels to produce and accumulate excess fibronectin. In mice engineered to carry the human APOE ε4 gene, the team measured nearly twice as much fibronectin as in mice carrying the more common APOE ε3 variant, accompanied by signs that the blood-brain barrier had become leaky — letting substances that should stay out of the brain seep in, a process linked to inflammation and neurodegeneration. The rare protective mutation appears to block that fibronectin buildup in the first place.
"This new study takes us from a genetic clue to a disease mechanism," said Caghan Kizil, the study's corresponding author and a professor of neurological sciences at Columbia's Vagelos College of Physicians and Surgeons and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, in a statement carried by ScienceDaily. "We knew that changes in fibronectin could protect against Alzheimer's, but we didn't know why excess fibronectin was harmful in the first place. This study gives us that detailed mechanism — and with it, ideas for how to reproduce that natural protection."
An earlier phase of the research found the fibronectin variant was linked to as much as a 70% lower chance of developing Alzheimer's among APOE ε4 carriers. The hope now, Kizil's team says, is to design drugs that mimic the rare mutation's effect on the blood-brain barrier without requiring the mutation itself — though that work remains in its early stages. The findings so far come from mouse, zebrafish, cell and tissue models rather than human clinical trials, and researchers caution that translating a protective mechanism into an approved treatment can take years, if it succeeds at all.
